CUREVAC N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.29 USD | +5.45% |
|
-2.08% | -21.85% |
| 07-03 | Health Stocks Slip in Risk-On Trade -- Health Care Roundup | DJ |
| 07-03 | Sector Update: Health Care Stocks Fall in Afternoon Trading | MT |
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve peopleâs lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
Calendar
2024-08-14
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
2.888
EUR
Average target price
7.169
EUR
Spread / Average Target
+148.23%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.85% | 700M | |
| +18.97% | 44.44B | |
| +41.98% | 40.03B | |
| -10.06% | 37.68B | |
| +31.15% | 31.46B | |
| -7.79% | 27.29B | |
| +13.32% | 26.29B | |
| +43.05% | 13.8B | |
| +31.28% | 12.46B | |
| -7.41% | 11.26B |
- Stock Market
- Equities
- CVAC Stock
- News CureVac N.V.
- Sector Update: Health Care
